News

MedSource announces the selection of Datatrial's nowEDC platform as its e-clinical software solution.

The Society for Clinical Research Sites (SCRS) and the Association of Black Cardiologists (ABC), with over 1,500 members, have partnered to increase diversity at the clinical research investigator level.

Catalent announces the launch of its FastChain service, which uses a continous GMP approach to clinical supply management.

Veeva Systems has released the results of their 2016 Paperless TMF Survey at the 2016 DIA Annual Meeting in Philadelphia.

Exco InTouch has announced a partnership with AliveCor in order to make mobile electrocardiogram (ECG) measurements available in clinical research.

Peter O’Donnell writes that Brexit or or no Brexit, it will be interesting to see how far the industry rules are complied with across Europe now that the EFPIA disclosure code is also in force.

The Society for Clinical Research Sites (SCRS) announced that US Oncology Research has become an SCRS member, joining over 2,800 research sites in 42 countries.

Biomedical Systems has opened its new technology and research center in St. Louis, Missouri near the company's global headquarters.

inVentiv Health Inc. announced that it has been selected by Pfizer Inc. as one of its preferred partners in the delivery of clinical operations services.

Bioclinica announced Parallel 6 as the newest member of its eHealth App xChange.

DrugDev has launched its CRO Preferred Partner program alongside Charter Member INC Research.

The agency offers its official comment following the UK's historic vote last week to leave the European Union.

The UK's EU departure threatens to damage the foundation of several European-wide drug safety and innovation initiatives, and also leaves recent boasts from officials on things like partnership, networking, and transparency just empty words.

Britain's unprecedented vote to leave the European Union will have major ramifications for the biopharma industry, including in areas such as drug regulation, R&D, IP rights, and market access.

The new offering, designed to enhance diabetes trials, combines wearable technology with Quintiles' therapeutic and analytical expertise.